BiotechTube

Glepaglutide

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Short Bowel Syndrome

Conditions

Short Bowel Syndrome

Trial Timeline

Feb 11, 2026 → Feb 28, 2032

NCT ID
NCT07197944

About Glepaglutide

Glepaglutide is a phase 3 stage product being developed by Zealand Pharma for Short Bowel Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07197944. Target conditions include Short Bowel Syndrome.

What happened to similar drugs?

5 of 14 similar drugs in Short Bowel Syndrome were approved

Approved (5) Terminated (2) Active (9)
✅Growth HormoneEli LillyApproved
✅Somatotropin growth hormone recombinant humanPfizerApproved
✅Genotropin (somatropin)PfizerApproved
✅GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatmentPfizerApproved
✅Nutropin [Somatropin (rDNA origin) for injection]IpsenApproved
🔄somatropin + leuprorelinEli LillyPhase 3
🔄Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth HormoneAstraZenecaPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (7)

NCT IDPhaseStatus
NCT07197944Phase 3Recruiting
NCT04991311Phase 3Completed
NCT04881825Phase 3Active
NCT04318743Phase 1Completed
NCT04178447Phase 1Completed
NCT03905707Phase 3Active
NCT03279302Phase 1Completed

Competing Products

20 competing products in Short Bowel Syndrome

See all competitors
ProductCompanyStageHype Score
somatropin + leuprorelinEli LillyPhase 3
40
Growth HormoneEli LillyApproved
35
Pancreatic EnzymeAbbViePhase 2
35
Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth HormoneAstraZenecaPhase 3
40
Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)MerckPhase 1
29
Saizen® + Saizen®MerckPhase 3
40
r-metHuLeptinAmgenPhase 1
29
Somapacitan + Norditropin®Novo NordiskPhase 2
39
Somatotropin growth hormone recombinant humanPfizerApproved
43
Genotropin (somatropin)PfizerApproved
43
Genotropin + GenotropinPfizerPhase 3
40
GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatmentPfizerApproved
43
GenotropinPfizerPhase 2/3
38
glepaglutideZealand PharmaPhase 3
41
GlepaglutideZealand PharmaPhase 3
41
ZP1848Zealand PharmaPhase 2
32
glepaglutide + PlaceboZealand PharmaPhase 3
37
GlepaglutideZealand PharmaPhase 3
37
Glepaglutide 10 mgZealand PharmaPhase 3
44
Nutropin [Somatropin (rDNA origin) for injection]IpsenApproved
32